Drs Ursula A. Matulonis and Gini F. Fleming discuss the state of endometrial cancer, the role of immunotherapy, and priorities for research in this field.

The TCGA found that patients with tumors with POLE mutations had the ... which actually correlated more with endometrioid histology, and copy number high, which is more serous-like.

“The most common type of endometrial cancer is endometrioid endometrial cancer and this is caused by excess estrogen or a lack of progesterone, both of which are female hormones,” she say ...

Mucinous, endometrioid, and clear cell cancers are less common and have unique characteristics and treatments. Germ cell ...

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient (dMMR), surgically resectable endometrial cancer, according to findings presented at the SGO 2025 Annual ...

The research team also assessed mutation rates for genes that are not included in a cancer type’s standard-of-care testing protocol. For example, 54 percent of uterine corpus endometrial carcinomas ...

with histologically confirmed endometrial cancer. All had ECOG performance status of 0 (28.1%) or 1 (71.9%). Nearly two-thirds (62.5%) had endometrioid adenocarcinoma, and 25% had received at ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...

Standard treatment for resectable endometrial cancer often consists of surgery ... and 14 (93.3%) had endometrioid histology. No women had received prior immune checkpoint inhibitor therapy.